Ascletis Drug Cuts Psoriasis Severity by 48.9 per Cent

Ascletis Announces Positive Results from 28-Day Proof-of-Concept Clinical Study in U.S. for ASC50, a First-in-Class and Best-in-Class Oral Small Molecule IL-17A Inhibitor for the Treatment of Plaque Psoriasis

48.9% placebo-adjusted reduction in psoriasis area and severity index (PASI) score achieved in mild-to-moderate plaque psoriasis patients with once-daily 200 mg 28-day treatment.

Ascletis challenges psoriasis field with pill; Invivyd plans Covid filing

Plus news about Breye, Immix and Aptadir. Ascletis takes on injectables with psoriasis pill: The Hong Kong-listed biotech is developing a small-molecule IL-17A inhibitor, going after the same target as injectables ...

Ascletis drug cuts psoriasis severity by 48.9 per cent

Biopharmaceutical firm Ascletis achieved a 48.9 per cent placebo-adjusted reduction in psoriasis severity scores during a 28-day clinical trial of its oral inhibitor ASC50 in the United States.